Warr D, Wilan A, Venner P, Pater J, Kaizer L, Laberge F, Latreille J, Stewart D, O'Connell G, Osoba D
Department of Medicine, Princess Margaret Hospital, Toronto, Ontario, Canada.
Eur J Cancer. 1992;29A(1):33-6. doi: 10.1016/0959-8049(93)90572-w.
151 patients (149 evaluable) receiving their first course of chemotherapy containing cisplatin in a dose of at least 50 mg/m2 were randomised to receive either a single dose of intravenous granisetron 80 micrograms/kg or intravenous metoclopramide 2 mg/kg every 2 h for five doses plus a single dose of dexamethasone 10 mg and diphenhydramine. After 24 h, there was no significant difference between groups with respect to nausea or vomiting: in the granisetron group 46% of patients had no emesis, versus 44% of the standard group. Granisetron is an antiemetic agent with efficacy similar to that of high-dose metoclopramide plus dexamethasone.
151例（149例可评估）接受含顺铂且剂量至少为50mg/m²的首个化疗疗程的患者被随机分为两组，一组接受单次静脉注射格拉司琼80微克/千克，另一组接受静脉注射甲氧氯普胺2毫克/千克，每2小时一次，共五次，加单次静脉注射地塞米松10毫克和苯海拉明。24小时后，两组在恶心或呕吐方面无显著差异：格拉司琼组46%的患者未发生呕吐，标准组为44%。格拉司琼是一种止吐药，其疗效与高剂量甲氧氯普胺加地塞米松相似。
